ase

Ambalal Sarabhai Enterprises Limited

Registered Office: Shantisadan, Mirzapur Road, Ahmedabad-380001.
Telephone: +9179-25507671 / 25507073, Fax: +9179-25507483, E-mail: ase@sarabhai.co.in

Ref. No.:

Date: 05.03. 2021

To,
BSE Limited
Listing Dept. /Dept. of Corporate Services
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001
Security Code: 500009

<u>Sub.</u>: Outcome of the meeting of Board of Directors held on 5th March, 2021 <u>Ref:</u> Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

In continuation to our corporate disclosure dated **26**th **November**, **2020 & 2**nd **January**, **2021** which were filed with exchange in due course and in line with the corporate disclosure requirement under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that:

Board of Directors of the Company had in its meeting held on 5th March,2021, has approved the change in consideration from Rs. 11,91, 87,640/- (Rupees Eleven Crore Ninety One Lakh Eighty Seven Thousand Six Hundred Forty Only) to Rs. 12,39,90,270/- (Rupees Twelve Crore Thirty Nine Lakhs Ninety Thousand Two Hundred Seventy only) and also extended the date of completion to 31.03.2021 for completion of sale / disposal in pursuant to Share Purchase Agreement (SPA) executed with Asence Pharma Private Limited for sale of equity shares of Synbiotics Limited, a wholly owned subsidiary to Asence Pharma Private Limited, another subsidiary of the Company.

The Sr. No. 3 & 4 of the Annexure 1 of shall be amended and read as under:

Sr. No.	Details of Events required to be disclosed	Disclosures
3	The expected date of completion of sale/disposal;	Up to 31.03.2021
4	Consideration received from such sale/disposal	Total consideration of Rs. 12,39,90,270/- (Rupees Twelve Crore Thirty Nine Lakhs Ninety Thousand Two Hundred Seventy only) shall be payable by the Asence Pharma Private Limited as under:
		1. By issuance of 90,00,000 Preference Shares (2% Redeemable Non-convertible Non-cumulative Participating Preference Shares) redeemable for a term of 20 years having face value of Rs. 10/-(Rupees Ten only) each amounting to Rs. 9,00,00,000/- (Rupees Nine Crore Only) in

ase

Ambalal Sarabhai Enterprises Limited

Registered Office: Shantisadan, Mirzapur Road, Ahmedabad-380001.
Telephone: +9179-25507671 / 25507073, Fax: +9179-25507483, E-mail: ase@sarabhai.co.in

Ref. No.	Ref. No.:			
Date :		favour of the Ambalal Sarabhai Enterprises Limited.		
		2. Balance amount for Rs. 3,39,90,270/- (Rupees Three Crore Thirty Nine Lakhs Ninety Thousand Two Hundred Seventy Only) shall be remained as Unpaid Purchase Price (Outstanding) interest per annum bearing at mutually decided by both the parties, which shall be paid within 20 years.		

AAIEN

The revised **Annexure 1** is attached herewith for your perusal.

You are requested to take the same on your record.

The meeting commenced on 11:00 AM and ended on 11:30 AM.

Thanking you,

For Ambalal Sarabhai Enterprises Limited

Damodar H. Sejpal

Company Secretary & Compliance Officer

Encl.: Annexure I



Ambalal Sarabhai Enterprises Limited

Registered Office: Shantisadan, Mirzapur Road, Ahmedabad-380001.
Telephone: +9179-25507671 / 25507073, Fax: +9179-25507483, E-mail: ase@sarabhai.co.in

Ref. No.:

Annexure - I

ste Sr. No.	Details of Events required to be disclosed	Disclosure
1.	The amount and percentage of the	% and amount contributed by Synbiotics Limited
	turnover or revenue or income and net	in Consolidate Turnover of the Company as on
	worth contributed by such unit or	31.03.2020:
	division of the listed entity during the	× ×
	last financial year	%: 2.65%
		Amount: Rs. 417.97 Lakhs
at at	e e e e e e e e e e e e e e e e e e e	% and amount contributed by Synbiotics Limited
	8.	in Consolidate Net worth of the Company as on
		31.03.2020:
	8 8	
		%:-26.62%
	2 1 a 1	Amount: Rs1191.89 Lakhs
		Timodit. RS. 1171.07 Editis
	2 a 2 a 2 a 2 a 2 a 2 a 2 a 2 a 2 a 2 a	
2.	Date on which the agreement for sale	27.11.2020
	will be entered into	
÷,		
3.*	The expected date of completion of	Up to 31.03.2021
a a	sale/ disposal;	
4.**	Consideration received from such	Total consideration of Rs. 12,39,90,270/-
	sale/ disposal	(Rupees Twelve Crore Thirty Nine Lakhs
	,	Ninety Thousand Two Hundred Seventy only)
	.t	shall be payable by the Asence Pharma Private
	e	Limited as under:
		1. By issuance of 90,00,000 Preference Shares
		(2% Redeemable Non-convertible Non-
	r fag. fag.	cumulative Participating Preference Shares)
		redeemable for a term of 20 years having face
		value of Rs. 10/- (Rupees Ten only) each
		amounting to Rs. 9,00,000/- (Rupees Nine
		Crore Only) in favour of the Ambalal Sarabhai
		Enterprises Limited.
		Enter prises Limited.
		2. Balance amount for Rs. 3,39,90,270/ -
		(Rupees Three Crore Thirty Nine Lakhs Ninety
		Thousand Two Hundred Seventy Only) shall
		be remained as Unpaid Purchase Price
		(Outstanding) interest per annum bearing at
		mutually decided by both the parties, which shall
		be paid within 20 years.



ase

Ambalal Sarabhai Enterprises Limited

Registered Office: Shantisadan, Mirzapur Road, Ahmedabad-380001.
Telephone: +9179-25507671 / 25507073, Fax: +9179-25507483, E-mail: ase@sarabhai.co.in

Ref. No.:

Date	5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group Companies. If yes, details thereof;	Asence Pharma Private Limited, subsidiary of the Company, is the buyer.
	6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	The transaction is falling under related party transactions and the said transaction is being entered into at arm's length.
5. ×	7.	In case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable

^{*} amended by the Board of Directors at their meeting held on 05.03.2021

For Ambalal Sarabhai Enterprises Limited SHALEN

Damodar H. Sejpal

Company Secretary & Compliance Officer

^{**} amended by the Board of Directors at their meeting held on 05.03.2021